#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Adrenogenital syndrome Thyroid cancer metastatic Neuroendocrine cell hyperplasia of infancy Selective polysaccharide antibody deficiency Leukodystrophy Breast cancer Kawasaki's disease Bone marrow disorder Multifocal motor neuropathy Chronic lymphocytic leukaemia refractory Acute graft versus host disease Lymphoma Pelizaeus-Merzbacher disease Thrombotic thrombocytopenic purpura Dementia More trials…

    Learn about Rare Diseases

    Glomerulonephritis rapidly progressive – Basic Information Prolymphocytic leukaemia – Treatment Burkitt’s lymphoma – Basic Information Choroid melanoma – Diagnostics Synovial sarcoma metastatic – Treatment Mucopolysaccharidosis – Trials in Disease Progressive supranuclear palsy – Trials in Disease Leiomyosarcoma metastatic – Trials in Disease Alport’s syndrome – Life with Disease VEXAS syndrome – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    RO7795081 Ads-010 Proline Amcenestrant Copanlisib Dihydrochloride TUVATEXIB Bt8009 Sepiapterin Pyrazinamide Dapirolizumab Pegol Pentixafor Gallium Ga-68 Bidridistrogene Xeboparvovec Imiquimod Pilocarpine Nitrate Eribulin Tamsulosin Hydrochloride Prednisolone Sodium Succinate Esflurbiprofen Paeonol Rocatinlimab More therapies…

    Learn about Your Condition

    Malignant neoplasm of choroid Glaucoma Adrenocortical carcinoma Haemoglobinuria Toxic nodular goitre Congenital aplastic anaemia Frontotemporal dementia Primary hypogonadism Anaemia Anal fistula Rectal cancer Cerebrovascular accident Exposure via breast milk Myxoid liposarcoma Cervix carcinoma stage I More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Hormone receptor positive breast cancer

  • A Study Comparing GDC-4198 Alone and with Giredestrant versus Abemaciclib with Giredestrant for Advanced Breast Cancer After Previous CDK4/6 Treatment

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Human epidermal growth factor receptor negative
    • Hormone receptor positive breast cancer
    • Breast cancer
    Investigated Drugs:
    • Giredestrant
    • Abemaciclib
    France Germany Italy Spain

  • Study of patritumab deruxtecan versus drug combination in patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive breast cancer
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Doxorubicin Hydrochloride, Liposomal
    • Patritumab Deruxtecan
    • Capecitabine
    France Germany Greece Hungary Italy Poland +1

  • Study on the Safety and Effectiveness of Capivasertib and Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer After Hormone Treatment

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Capivasertib
    Belgium Germany Portugal

  • Study on the Effects of Ketorolac and Pregabalin in Patients Undergoing Surgery for Early Estrogen Receptor-Positive Breast Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone receptor positive breast cancer
    Investigated Drugs:
    • KETOROLAC
    • Pregabalin
    Belgium

  • Study on Oxybutynin and Venlafaxine for Reducing Hot Flashes in Women Undergoing Endocrine Therapy After Breast Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone refractory breast cancer
    • Triple positive breast cancer
    • Hormone receptor positive breast cancer
    Investigated Drugs:
    • Leuprorelin
    • Oxybutynin
    • Tamoxifen
    The Netherlands

  • Study Comparing MK-2870 and Pembrolizumab with Chemotherapy for Patients with Advanced Hormone Receptor Positive Breast Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Doxorubicin Hydrochloride, Liposomal
    • H2-Receptor Antagonists
    • Buclizine Hydrochloride
    Belgium Czechia Denmark France Germany Greece +10
1 2 3 … 7
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!